Research across Embolism and Thrombosis
Related studies from across the Embolism and Thrombosis family.
24 trials tracked for Thrombosis: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 764 citations.
Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical evidence regarding pharmacological interventions for thrombosis includes the use of Clopidogrel, which demonstrated a significant change in maximal platelet aggregation (p<0.001) compared to Ticagrelor, which showed no significant change (p=0.75) 1. Other established trials evaluated Desirudin 3, Apixaban [7, 12, 19], and Rivaroxaban 6.
BAY 59-7939 was shown to significantly reduce the composite of fatal or non-fatal symptomatic recurrent venous thromboembolism (p=0.0001) and the composite of primary efficacy outcomes including myocardial infarction, ischemic stroke, or systemic non-CNS embolism (p<0.0001), while not showing a statistically significant difference in first treatment-emergent major bleeding (p=0.3235) 4.
In specific clinical contexts, Acetylsalicylic acid was associated with a significant reduction in the rate of patients with at least one prosthetic leaflet with >50% motion reduction (p=0.01) and an improvement in aortic transvalvular mean pressure gradient (p=0.01) 5. Rivaroxaban data included measurements of absolute prothrombin time (PT) post-dose 6.
AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Embolism and Thrombosis family.